Thromboangiitis obliterans: a rheumatologist’s perspective
https://doi.org/10.14412/1996-7012-2025-5-119-126
Abstract
Thromboangiitis obliterans (TAO), or Buerger’s disease, is a segmental thrombotic acute and chronic inflammatory process in small- and mediumsized arteries and veins, primarily of the upper and lower extremities. In rare cases, cerebral, coronary, renal, and mesenteric vessels may also be affected. This review describes the rheumatologic manifestations of TAO, outlines the spectrum of diseases for differential diagnosis, and presents the updated diagnostic criteria for TAO (2023).
Keywords
Supporting agencies: The article was prepared within the framework of the basic research project № PK 125020501434-1.
About the Authors
N. V. Seredavkina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Nataliya Valeryevna Seredavkina
34A, Kashirskoe Shosse, Moscow 115522
T. M. Reshetnyak
V.A. Nasonova Research Institute of Rheumatology ; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
2/1, Barrikadnaya Street, Build. 1, Moscow 125993
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology ; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
2/1, Barrikadnaya Street, Build. 1, Moscow 125993
References
1. Fazeli B, Poredos P, Kozak M, et al. Diagnostic criteria for Buerger's disease: International Consensus of VAS – European Independent Foundation in Angiology/Vascular Medicine. Int Angiol. 2023 Oct;42(5):396-401. doi: 10.23736/S0392-9590.23.05098-8.
2. Espinoza LR. Buerger's disease: thromboangiitis obliterans 100 years after the initial description. Am J Med Sci. 2009 Apr;337(4): 285-6. doi: 10.1097/MAJ.0b013e318198d011.
3. Fazeli B, Poredos P, Patel M, et al. Milestones in thromboangiitis obliterans: a position paper of the VAS-European independent foundation in angiology/vascular medicine. Int Angiol. 2021 Oct;40(5):395-408. doi: 10.23736/S0392-9590.21.04712-X.
4. Pokrovski AV, Dan VN, Chupin AV. New aspects in the diagnosis and treatment of thromboangiitis obliterans (Buerger's disease). Angiologiya i sosudistaya khirurgiya. 2010;16(4): 175-183. (In Russ.).
5. Fazeli B, Ligi D, Keramat S, et al. Recent Updates and Advances in Winiwarter-Buerger Disease (Thromboangiitis Obliterans): Biomolecular Mechanisms, Diagnostics and Clinical Consequences. Diagnostics (Basel). 2021 Sep 22;11(10):1736. doi: 10.3390/diagnostics11101736.
6. Sapelkin SV, Druginina NA. Thromboangiitis obliterans (Buerger's disease). Consilium Medicum. 2018;20(8):91-95. (In Russ.).
7. Komai H. Thromboangiitis obliterans – A Disappearing Disease? Circ J. 2024 Feb 22;88(3):329-330. doi: 10.1253/circj.CJ-23-0524.
8. Shionoya S. Diagnostic criteria of Buerger’s disease. Int J Cardiol 1998 Oct 1:66 (Suppl 1): S243–5. doi: 10.1016/s0167-5273(98)00175-2.
9. Papa MZ, Rabi I, Adar R. A point scoring system for the clinical diagnosis of Buerger's disease. Eur J Vasc Endovasc Surg. 1996 Apr; 11(3):335-9. doi: 10.1016/s1078-5884(96)80081-5.
10. Adar R, Papa MC, Halperin Z, et al. Cellular sensitivity to collagen and thromboangiitis obliterans. N Engl J Med. 1983 May 12;308(19):1113–16. doi: 10.1056/NEJM198305123081901.
11. Kobayashi M, Ito M, Nakagawa A et al. Immunohistochemical analysis of arterial wall cellular infiltration in Buerger’s disease (endarteritis obliterans). J Vasc Surg. 1999 Mar;29:451–58. doi: 10.1016/s0741-5214(99)70273-9.
12. Eichhorn J, Sima D, Lindschau C et al. Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci 1998 Jan; 315(1):17–23. doi: 10.1097/00000441-199801000-00004.
13. Bilora F, Sartori MT, Zanon E, et al. Flow-mediated arterial dilation in primary antiphospholipid syndrome. Angiology. 2009 Feb-Mar;60(1):104-7. doi: 10.1177/0003319708315304.
14. Iwamoto A, Kajikawa M, Maruhashi T, et al. Vascular Function and Intima-media Thickness of a Leg Artery in Peripheral Artery Disease: A Comparison of Buerger Disease and Atherosclerotic Peripheral Artery Disease. J Atheroscler Thromb. 2016 Nov 1;23(11): 1261-1269. doi: 10.5551/jat.35436.
15. Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (a lecture). Nauchno-prakticheskaya revmatologiya. 2014;52(1):56-71. (In Russ.).
16. Barbhaiya M, Zuily S, Naden R, et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2023 Oct;82(10):1258-1270. doi: 10.1136/ard-2023-224609.
17. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677-86. doi: 10.1002/art.34473.
18. Fernandez-Miranda C, Rubio R, Vicario JL, et al. Thromboangiitis obliterans (Buerger’s disease). Study of 41 cases. Med Clin (Barc). 1993 Sep 25;101(9):321–6.
19. Adar R, Papa MZ, Schneiderman J. Thromboangiitis obliterans: an old disease in need of a new look. Int J Cardiol. 2000 Aug 31:75 (Suppl 1):S167-70; discussion S171-3. doi: 10.1016/s0167-5273(00)00185-6.
20. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002 Apr;46(4):1019-27. doi: 10.1002/art.10187.
21. Maslowski L, McBane R, Alexewicz P, Wysokinski WE. Antiphospholipid antibodies in thromboangiitis obliterans. Vasc Med. 2002; 7(4):259-64. doi: 10.1191/1358863x02vm452oa.
22. Atsumi T, Chighizola CB, Fujieda Y, et al. 16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome laboratory diagnostics and trends. Lupus. 2023 Dec;32(14):1625-1636. doi: 10.1177/09612033231211820.
23. Merashli M, Bucci T, Pastori D, et al. Antiphospholipid antibodies and lower extremity peripheral artery disease: A systematic review and meta-analysis. Semin Arthritis Rheum. 2020 Dec;50(6):1291-1298. doi: 10.1016/j.semarthrit.2020.08.012.
24. Vikerfors A, Johansson AB, Gustafsson JT, et al. Clinical manifestations and antiphospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology (Oxford). 2013 Mar;52(3):501–9. doi: 10.1093/rheumatology/kes252.
25. Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. Lupus. 2010 Apr;19(4):419–23. doi: 10.1177/0961203309360541.
26. Vasugi Z, Danda D. Systemic lupus erythematosis with antiphospholipid antibody syndrome: a mimic of Buerger's disease. J Postgrad Med. 2006 Apr-Jun;52(2):132-3.
27. Giannakakis S, Galyfos G, Stefanidis I, et al. Hybrid treatment of lower limb critical ischemia in a patient with systemic lupus erythematosus. Ann Vasc Surg. 2015 Apr;29(3): 596.e1-5. doi: 10.1016/j.avsg.2014.10.040.
28. Panafidina TA, Popkova TV. Heart failure in systemic lupus erythematosus: risk factors and diagnostic features. Nauchno-Prakticheskaya Revmatologiya. 2018;56(3):380-385. (In Russ.).
29. Ajeganova S, Hafström I, Frostegеrd J. Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid syndrome: a case-control study over 10 years. Lupus Sci Med. 2021 Feb;8(1):e000454. doi: 10.1136/lupus-2020-000454.
30. Forte F, Buonaiuto A, Calcaterra I, et al. Association of systemic lupus erythematosus with peripheral arterial disease: a meta-analysis of literature studies. Rheumatology (Oxford). 2020 Nov;59(11):3181-3192. doi: 10.1093/rheumatology/keaa414.
31. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. doi: 10.1002/art.37715.
32. Islam MA, Alam SS, Kundu S, et al. Prevalence of antiphospholipid antibodies in Behcet's disease: A systematic review and meta-analysis. PLoS One. 2020 Jan 13;15(1): e0227836. doi: 10.1371/journal.pone.0227836.
33. al-Dalaan AN, al-Ballaa SR, al-Janadi MA, et al. Association of anti-cardiolipin antibodies with vascular thrombosis and neurological manifestation of Behзets disease. Clin Rheumatol. 1993 Mar;12(1):28-30. doi: 10.1007/BF02231554.
34. Hari G, Skeik N. Digital ischemia in Behcet's disease: case-based review. Rheumatol Int. 2020 Jan;40(1):137-143. doi: 10.1007/s00296-019-04452-z.
35. Jbiniani O, Hammami S, Bdioui F, et al. The Budd-Chiari syndrome and Buerger's disease: a case report. Tunis Med. 2009 Oct; 87(10):706-708.
36. Fakour F, Fazeli B. Visceral bed involvement in thromboangiitis obliterans: a systematic review. Vasc Health Risk Manag. 2019 Aug 15:15:317-353. doi: 10.2147/VHRM.S182450.
37. Puechal X, Fiessinger JN, Kahan A, Menkes CJ. Rheumatic manifestations in patients with thromboangiitis obliterans (Buerger's disease). J Rheumatol. 1999 Aug;26(8): 1764-8.
38. Johnson JA, Enzenauer RJ. Inflammatory arthritis associated with thromboangiitis obliterans. J Clin Rheumatol. 2003 Feb;9(1):37–40. doi: 10.1097/01.RHU.0000049712.74443.70.
39. Lambotte O, Chazerain P, Vinciguerra C, et al. Thromboangiitis obliterans with inaugural rheumatic manifestations. A report of three cases. Rev Rhum Engl Ed. 1997 May;64(5): 334-8.
40. Takanashi T, Horigome R, Okuda Y, et al. Buerger’s disease manifesting nodular erythema with livedo reticularis. Intern Med. 2007; 46(21):1815-9. doi: 10.2169/internalmedicine.46.0143.
41. Chen HH, Chao WC, Chen YH, et al. Risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study. Arthritis Res Ther. 2019 Aug 29; 21(1):196. doi: 10.1186/s13075-019-1980-1.
42. Lopalco G, Iannone F, Rigante D, et al. Coexistence of axial spondyloarthritis and thromboangiitis obliterans in a young woman. Reumatismo. 2015 Jun 30;67(1):17-20. doi: 10.4081/reumatismo.2015.810.
43. Diaz-Pena R, Vidal-Castineira JR, LopezVazquez A, Lopez-Larrea C. HLA-B*40:01 is associated with ankylosing spondylitis in HLA-B27-positive populations. J Rheumatol. 2016 Jun;43(6):1255–6. doi: 10.3899/jrheum.151096.
44. Siddiqui MZ, Reis ED, Soundararajan K, Kerstein MD. Buerger's disease affecting mesenteric arteries: a rare cause of intestinal ischemia – a case report. Vasc Surg. 2001 May-Jun;35(3):235-8. doi: 10.1177/153857440103500314.
45. Burke AP, Sobin LH, Virmani R. Localized vasculitis of the gastrointestinal tract. Am J Surg Pathol. 1995 Mar;19(3):338-49. doi: 10.1097/00000478-199503000-00012.
46. Li QL, He DH, Huang YH, Niu M. Thromboangiitis obliterans in two brothers. Exp Ther Med. 2013 Aug;6(2):317–320. doi:10.3892/etm.2013.1160.
47. Fazeli B, Poredos P, Schernthaner G, et al. An International Delphi Consensus on Diagnostic Criteria for Buerger's Disease. Ann Vasc Surg. 2022 Sep:85:211-218. doi: 10.1016/j.avsg.2022.03.028.
Review
For citations:
Seredavkina NV, Reshetnyak TM, Lila AM. Thromboangiitis obliterans: a rheumatologist’s perspective. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2025;19(5):119-126. (In Russ.) https://doi.org/10.14412/1996-7012-2025-5-119-126
Views:
26
Email this article 